Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 4/20 | 0.36 |
| ▸ | DBH | P09172 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.33 |
| ▸ | PDE2A | O00408 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | TUBB1 | Q9H4B7 | 3/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.32 |
| ▸ | HTR2C | P28335 | 1/20 | 0.32 |
| ▸ | HTR2B | P41595 | 1/20 | 0.32 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.32 |
| ▸ | APP | P05067 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8514861 | 1.00 | ADRB2 (0.36) | ADRB2DBHDPP4PDE2AACACB | |
| SCHEMBL8511259 | 0.81 | TRPV3 (0.41) | ADRB2PDE2ATUBB1 | |
| SCHEMBL8511262 | 0.81 | TRPV3 (0.41) | ADRB2PDE2ATUBB1 | |
| SCHEMBL8173411 | 0.79 | MAPT (0.47) | TUBB1HTR2AHTR2CHTR2B | |
| SCHEMBL8511277 | 0.78 | CES2 (0.39) | ADRB2DPP4PDE2A | |
| SCHEMBL1239524 | 0.78 | CES2 (0.39) | ADRB2DPP4PDE2A | |
| SCHEMBL15517307 | 0.77 | PDE2A (0.47) | PDE2ATUBB1 | |
| SCHEMBL15517309 | 0.77 | PDE2A (0.47) | PDE2ATUBB1 | |
| SCHEMBL507050 | 0.76 | PDGFRB (0.33) | ADRB2DBHPDE2AACACBTUBB1 | |
| Hydrochloric Acid SCHEMBL15511806 | 0.76 | PDE2A (0.46) | ADRB2PDE2ATUBB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2643313-B9 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2017-02-22 | — | — | EP | disclosed |
| EP-2643313-B1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2016-06-29 | — | — | EP | disclosed |
| US-8946247-B2 | Quinazoline carboxamide azetidines | MERCK PATENT GMBH (DE) | 2015-02-03 | — | — | US | disclosed |
| EP-2643313-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | Merck Patent GmbH (DE) | 2013-10-02 | — | — | EP | disclosed |
| US-20130252942-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2013-09-26 | — | — | US | disclosed |
| WO-2012069146-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | MERCK PATENT GMBH (DE) | 2012-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130252942-A1 | QUINAZOLINE CARBOXAMIDE AZETIDINES | AZI2, NQO2, ABL1 | ADRB2 1632/4885DBH 3435/4885DPP4 1055/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.